Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals’ phase 3 Lucidity trial showed avexitide reduced serious hypoglycemic events by 55% vs placebo, supporting an FDA submission timeline by end-2024 and a potential 2027 launch. The company also raised $500 million via a stock offering at $35.50/share, adding balance-sheet runway but diluting existing holders. After a 247% YTD rally, valuation remains the key risk, with analysts citing peak U.S. sales potential of about $1.5B; the article suggests a more attractive entry on a ~15%–20% pullback to ~$28–$30.

Analysis

The financing changes the stock from a balance-sheet repair story to an execution story, which is positive for survival but also removes the last easy excuse for a rerating. At this valuation, the market is already discounting a clean regulatory path and a meaningful fraction of peak sales, so any slippage in filing timing or label scope should compress the multiple quickly even if the phase 3 data remain intact.

The main second-order winner is not obvious competitors, but the ecosystem around PBH diagnosis and treatment: endocrinology clinics, bariatric centers, and specialty pharmacies gain a reimbursable branded therapy category if avexitide is approved. The losers are payers and existing ad hoc management approaches, because a first-in-class treatment tends to expand diagnosed incidence rather than just steal share. The bigger risk is that a narrow patient population, reimbursement friction, and slow specialist adoption make peak-sales estimates look aggressive; this is a 1-3 year commercialization story, not a near-term earnings story.

Consensus is underestimating the gap between "positive phase 3" and durable franchise economics. The hard part is not the filing, it is payer coverage, patient identification, and whether the label is broad enough to support uptake without forcing a discount-heavy launch. Falsifiers are simple: an FDA information request, delayed submission beyond year-end, or a post-rally break below the low-$30s that signals the market is no longer willing to pay for 2027 optionality.

Key Decisions for Investors

• Do not chase AMLX after the 247% move; wait for a retracement toward $28-$30 before initiating a starter long. That range offers a better risk/reward because it reduces the post-offering air pocket while still preserving upside to the first FDA milestone.
• If you need exposure now, use a limited-risk structure rather than outright shares: buy a 12-18 month call spread on AMLX sized small, targeting the FDA submission/PDUFA path rather than the 2027 launch. The trade works only if the market keeps paying for pipeline optionality.
• Market-neutral expression: long AMLX vs short XBI/IBB. That isolates the idiosyncratic regulatory catalyst while hedging broad biotech multiple compression if rates or risk appetite turn.
• Set a catalyst alert on the end-of-year FDA filing and acceptance. Any delay, narrower-than-expected label, or need for additional study is a thesis breaker and should be treated as a de-risk event, not a buy-the-dip moment.